Lumexa Imaging Holdings

LMRI

Market cap $1B

RALEIGH, N.C., July 29, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced it will release its second quarter 2026 financial and operational results after market close on Wednesday, August 12, 2026.

Terumo, QuidelOrtho, Lumexa Imaging and BrainsWay are tackling industry headwinds through innovation, pricing and execution as healthcare demand stays resilient.

The mean of analysts' price targets for Lumexa (LMRI) points to a 44.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The consensus price target hints at a 73.3% upside potential for Lumexa (LMRI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

RALEIGH, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced the formation of a strategic joint venture with Hospital for Special Surgery (HSS), world leader in musculoskeletal health.

Lumexa Imaging Holdings, Inc. (LMRI) Q1 2026 Earnings Call Transcript

Lumexa Imaging NASDAQ: LMRI reported first-quarter results that management said were in line with expectations, as growth in advanced imaging modalities helped offset seasonal volume pressure and weather-related disruptions.

RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (Nasdaq: LMRI), one of the nation's largest providers of outpatient imaging services, today announced results for the first quarter ended March 31, 2026, and reiterated full year 2026 guidance.

RALEIGH, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Lumexa Imaging (NASDAQ: LMRI), one of the nation's largest providers of outpatient imaging services, today announced the addition of four new locations in 2026 as part of its continued execution against a disciplined, multi-channel growth strategy.

Shares of Lantheus Holdings were added after the company received FDA approval of its key product TruVu. We used recent weakness as an opportunity to initiate a position in Talen Energy, an independent power producer whose portfolio includes the Susquehanna nuclear plant and other dispatchable generation assets. We exited Cactus as we lost confidence that its major growth lever, expansion into the Middle East, would play out in 2026 amid the escalating conflict in the region.